Company news
CRISPR Therapeutics AG news in 2023
CRISPR Therapeutics AG's news releases, calls and decks from 2023, newest first.
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
December 7, 2023
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
December 3, 2023
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
November 15, 2023
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 5, 2023
CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
November 5, 2023
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
October 30, 2023
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
October 30, 2023
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
September 26, 2023
CRISPR Therapeutics Announces Leadership Transition
September 6, 2023
CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference
August 29, 2023
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 6, 2023
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
June 12, 2023
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
June 8, 2023
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
June 7, 2023
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
May 7, 2023
CRISPR Therapeutics to Participate Upcoming Investor Conferences
May 1, 2023
CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
April 12, 2023
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
April 2, 2023
CRISPR Therapeutics Announces Departure of Board Member
March 28, 2023
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
March 26, 2023
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
March 13, 2023
CRISPR Therapeutics Announces Transition of Chief Financial Officer
March 12, 2023
CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
February 26, 2023
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 20, 2023
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
January 10, 2023